vectors. Its technology is designed to support repeat dosing, targeted biodistribution across multiple organs, and delivery of genetic payloads without size limitations. SonoThera conducts research and development programs focused on conditions affecting muscle, kidney, liver, heart, and other tissues, with therapeutic candidates aimed at addressing underlying genetic causes of disease. The company also advances proprietary delivery technologies that support the development of gene replacement, gene editing, and other nucleic acid-based treatments.